Clinical Trial Search

Primary: Percentage of Participants With Virologic Rebound (HIV-1 RNA >=50 Copies/mL) Cumulative Through Week 48 — 2.5; 2.1 Percentage of participants — p=<0.001

Primary: Global Face Total Lesion Count - Percent Change - Baseline to Week 12 — -42.64; -47.80 Percent Change in Lesions — p=0.538

Primary: Percentage of Participants Admitted to the Hospital for Headache — 6.0; 2.1 percentage of participants

Primary: Postoperative Pain as Measured on a 11-point Numerical Rating Scale — 3.5; 4.9 units on a scale — p=0.009

Primary: Percentage of Participants With Engraftment — 100 percentage of participants

Primary: Number of Participants Who Experience at Least One Adverse Drug Reactions (ADRs) — 283 Participants

Primary: Success of Spinal Labor Analgesia From Combined Spinal Epidural — 163; 161 Participants — p=>.05

Primary: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuation Due to AEs, Withdrawals Due to AEs — 358; 148; 91; 90 Participants

Primary: Change in Colonic Transit Time From Baseline to Day 15 — -1.7; 4.0; 2.5; 2.6 Hours

Primary: Suture Location in Relation to the Surrounding Anatomy — 2.5; 2.8; 2.2; 2.2 cm

Primary: Change From Baseline in 1-hour Morning Post-dose Dose Forced Expiratory Volume in 1 Second (FEV1) of AB/FF 400/12 μg Compared to AB 400 μg at Week 24 — 0.253; 0.169…

Primary: Validated the Next Generation Oximeter — 1.22; 0.83; 0.09 Percentage saturation

Primary: Maximum Observed Concentration (Cmax) of Belimumab — 221.3532 Micrograms per milliliter

Primary: Number of Participants Who Experienced an Adverse Event (AE) — 3; 3; 3; 3 Participants

Primary: Success Rates of the Procedure — 272; 1; 26 Participants — p=<0.0001